Natixis Advisors, L.P. Alkermes Plc. Transaction History
Natixis Advisors, L.P.
- $54.1 Billion
- Q1 2025
A detailed history of Natixis Advisors, L.P. transactions in Alkermes Plc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 57,067 shares of ALKS stock, worth $1.77 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
57,067
Previous 49,922
14.31%
Holding current value
$1.77 Million
Previous $1.44 Million
31.2%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ALKS
# of Institutions
410Shares Held
177MCall Options Held
229KPut Options Held
436K-
Black Rock Inc. New York, NY29.1MShares$902 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$565 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.8MShares$365 Million0.05% of portfolio
-
State Street Corp Boston, MA8.02MShares$249 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.88MShares$213 Million3.72% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.09B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...